Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma in the EU5 and a common indication for liver transplantation. The 2013-2015 EMA…
Hepatitis C virus (HCV) is the leading cause of end-stage liver disease and hepatocellular carcinoma in China and South Korea. The prevalence of this chronic disease remains high owing to the…
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma and are a common indication for liver transplantation. The 2013-2015 FDA…
Hepatitis C virus (HCV) is the leading cause of end-stage liver disease and hepatocellular carcinoma in China. The prevalence of this chronic disease remains high owing to the presence of a large…
Last Updated 8 December 2015 The hepatitis C virus (HCV) therapy market is undergoing unprecedented growth. Commercial opportunity is driven by a large prevalent population and historically high…
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma and are a common reason for liver transplantation in Europe. The recent market…
Tackling the Market Access Challenges in Brazil, Mexico, and Argentina Increases in seroprevalent cases of hepatitis C virus (HCV), disease awareness, and patient access to HCV treatment create…
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma and are a common indication for liver transplantation. The late 2013 FDA…
The Impact of Premium-Priced Market Entrants on MCO-Run Medicare and Medicaid Plans The groundbreaking therapies for the Hepatitis C virus (HCV) promise high cure rates for millions of Americans…
How Will New Market Entrants Fare in the Rapidly Evolving Treatment Landscape? Affecting at least 170 million people worldwide, chronic hepatitis C virus (HCV) infections are a serious public…
Last Updated 29 December 2014 Hepatitis C virus (HCV) is the leading cause of end-stage liver disease and hepatocellular carcinoma. Treatment of it represents a large untapped market owing to high…
Prevalence of the hepatitis C virus (HCV) in Brazil is estimated to be among the highest in the world; in addition, the country faces the challenge of treating a largely undiagnosed HCV-infected…
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma and are a common indication for liver transplantation in Europe. The recent…
In January 2014, the European Medicines Agency granted marketing authorization to the first nucleotide polymerase inhibitor, sofosbuvir (Gilead’s Sovaldi), for the treatment of hepatitis C virus…
The primary goal of hepatitis C virus (HCV) treatment is to completely eliminate the virus from the patient’s body and thereby reduce or halt the progression of liver fibrosis, preventing further…